Cannabis Science Cheers Dr. Oz on Becoming a Vocal Supporter of Medical Marijuana on The Larry King Live Show
On the Heels of Dr. Sanjay Gupta, Dr. Oz Comes Out to Support Medicinal Marijuana Use
May 27, 2014 --
COLORADO SPRINGS, Colo., May 27, 2014 /PRNewswire/ -- Cannabis Science, Inc. (OTC-QB: CBIS), a U.S. Company specializing in the development of cannabis based medicine is glad to see a new milestone has been reached with Dr. Oz announcing on The Larry King Live show that his view has changed about medical marijuana use.
During an interview on Monday, May 12th, 2014, celebrity doctor Dr. Mehmet Oz, spoke with Larry King about his new perspective on the use of marijuana, particularly medical marijuana use.
Dr. Oz explains, "I grew up like most of my generation believing that marijuana was something (_____) was throwing at Americansbut I think most of us have come around to believe that marijuana is hugely beneficial when used correctly for medicinal purposes." Because smoking produces a psychoactive effect, however, Dr. Oz does warn against repeated recreational use, "...we pervert its use sometimes and I don't think it should be widely used, certainly not by kids because it creates a dependence that is unhealthy in any setting. But it absolutely should be widely available in America (for medical use)."
Read more about Dr. Oz on Larry King and watch a clip of the show at either of the following links:
Dr. Oz is a cardiothoracic surgeon and teaching professor at Columbia University. He became famous as a regular guest on The Oprah Show but eventually went on to host his own successful American syndicated television talk, The Dr. Oz Show. It debuted in the fall of 2009 and it is now in its fifth season.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.
Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.
Robert Kane, CFO & Director
SOURCE Cannabis Science, Inc.
Copyright 2014 PR Newswire. All Rights Reserved